Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.
2.

Azacitidine for the treatment of myelodysplastic syndrome.

Cataldo VD, Cortes J, Quintás-Cardama A.

Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. doi: 10.1586/era.09.61. Review.

PMID:
19589026
3.

The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Barbarotta L, Podoltsev N, Zeidan AM.

Expert Rev Anticancer Ther. 2015;15(9):1019-36. doi: 10.1586/14737140.2015.1061936. Epub 2015 Aug 17. Review.

PMID:
26292903
4.

Therapy with azanucleosides for myelodysplastic syndromes.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Nat Rev Clin Oncol. 2010 Aug;7(8):433-44. doi: 10.1038/nrclinonc.2010.87. Epub 2010 Jun 15. Review.

PMID:
20551943
5.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22. Review.

PMID:
20567826
6.

Advances in myelodysplastic syndrome: nursing implications of azacitidine.

Demakos EP, Linebaugh JA.

Clin J Oncol Nurs. 2005 Aug;9(4):417-23. Review.

PMID:
16117208
7.

5-Azacytidine for the treatment of myelodysplastic syndromes.

Krawczyk J, Keane N, Freeman CL, Swords R, O'Dwyer M, Giles FJ.

Expert Opin Pharmacother. 2013 Jun;14(9):1255-68. doi: 10.1517/14656566.2013.794222. Epub 2013 Apr 27. Review.

PMID:
23621771
8.

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

Leone G, Voso MT, Teofili L, Lübbert M.

Clin Immunol. 2003 Oct;109(1):89-102. Review.

PMID:
14585280
9.

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.

Santini V.

Expert Rev Hematol. 2009 Apr;2(2):121-7. doi: 10.1586/ehm.09.6. Review.

PMID:
21083445
11.

Myelodysplastic syndromes: therapy and outlook.

Lyons RM.

Am J Med. 2012 Jul;125(7 Suppl):S18-23. doi: 10.1016/j.amjmed.2012.04.018. Review.

PMID:
22735747
12.

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.

Ritchie EK.

Clin Interv Aging. 2012;7:165-73. doi: 10.2147/CIA.S24659. Epub 2012 Jun 19. Review.

13.

Epigenetic therapy in myelodysplastic syndromes.

Musolino C, Sant'antonio E, Penna G, Alonci A, Russo S, Granata A, Allegra A.

Eur J Haematol. 2010 Jun;84(6):463-73. doi: 10.1111/j.1600-0609.2010.01433.x. Epub 2010 Feb 23. Review.

PMID:
20192987
14.

Myelodysplastic syndromes: Contemporary review and how we treat.

Gangat N, Patnaik MM, Tefferi A.

Am J Hematol. 2016 Jan;91(1):76-89. doi: 10.1002/ajh.24253. Review.

15.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

PMID:
20507806
16.

Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.

Martino M, Fedele R, Moscato T, Ronco F.

Curr Cancer Drug Targets. 2013 Jul;13(6):661-9. Review.

PMID:
23713435
17.

Current and novel therapeutic approaches in myelodysplastic syndromes.

Estephan F, Tiu RV.

J Community Support Oncol. 2014 Jul;12(7):236-49. doi: 10.12788/jcso.0057. Review.

PMID:
25830232
18.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Fenaux P, Ades L.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9. Review.

PMID:
20004796
19.

DNA methyltransferase inhibitors in myelodysplastic syndrome.

Silverman LR.

Best Pract Res Clin Haematol. 2004 Dec;17(4):585-94. Review.

PMID:
15494296
20.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808

Supplemental Content

Support Center